证券代码：600422 证券简称：昆药集团 公告编号：2024-039号 昆药集团股份有限公司关于聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据公司发展及生产经营管理的需要，昆药集团股份有限公司（以下简称"昆药 集团"或"公司"）于 2024 年 6 月 25 日召开十届二十九次董事会，审议通过了《关 于聘任公司副总裁的议案》，经董事会提名委员会审核通过，公司董事会同意聘任高 童先生、孙成先生为公司副总裁(简历附后)，任期自本次董事会审议通过之日起至十 届董事会任期届满之日止。 高童先生、孙成先生未受过中国证监会及其他有关部门的处罚和证券交易所惩 戒；其任职资格及推荐程序符合《公司法》《公司章程》的相关规定。 孙成，男，1982 年生，硕士学位。曾任葵花集团股份有限公司商务总监、广州医药集团有限 公司营销总监、南京同仁堂药业有限责任公司销售公司副总经理兼处方事业部总经理、浙江苏泊 尔南洋药业有限公司营销副总裁、昆药集团营销有限公司 CHC（消费者健康管理平台）执行总裁； 现任昆药集团股份有限公司副 ...

昆药集团股份有限公司 KPC Pharmaceuticals, Inc. 2023 年年度股东大会 会 议 资 料 股票简称：昆药集团 股票代码：600422 2024 年 6 月 2023 年年度股东大会会议资料 会 议 须 知 为适应上市公司规范运作，提高股东大会议事效率，保障股东合法权益，确保大 会程序合法性，根据《中华人民共和国公司法》《中华人民共和国证券法》《公司章 程》以及《公司股东大会议事规则》等精神，特制定如下大会须知，望出席昆药集团 股份有限公司（以下简称"昆药集团"或"公司"）股东大会的全体人员严格遵守： 一、本次股东大会由公司董事会办公室具体负责大会的组织工作。 二、董事会以维护股东的合法权益，确保大会正常秩序和议事效率为原则，认真 履行法定职责。 三、出席本次股东大会的股东，依法享有发言权、表决权等各项权利。 四、会议期间请保持会场纪律、严肃对待每一项议题，会议期间全过程录音。 五、股东及股东代表参加本次股东大会，应当认真履行法定义务，不得侵犯其他 股东的权益，不得扰乱大会的正常程序和会议秩序。 六、会议议题全部说明完毕后统一审议、统一表决；股东大会采取现场投票和网 络投票相结合的表决 ...

证券代码：600422 证券简称：昆药集团 公告编号：2024-031号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 担保情况概述 （1）担保事项履行的相关程序 为支持昆药集团股份有限公司（以下简称"公司"）旗下全资及控股子公司 2024 年 生产经营及业务发展需要，满足相关下属公司融资担保需求，经公司十届二十三次董 事会及 2024 年第三次临时股东大会审议通过，2024 年度由公司及下属子公司为旗下 公司合计不超过人民币 6.06 亿元的银行融资授信业务提供连带责任担保，详见《昆药 集团股份有限公司关于 2024 年度担保计划的公告》（2024-015 号）和《昆药集团股 份有限公司 2024 年第三次临时股东大会决议公告》（2024-028 号）。 （2）担保概况 1 被担保人：曲靖市康桥医药有限责任公司（以下简称"曲靖康桥"），被担保人为公 司下属全资子公司昆药集团医药商业有限公司（以下简称"昆药商业"）的控股子 公司，不存在关联担保。 本次担保金额 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,852,637,983.31, a decrease of 3.01% compared to the same period last year[14] - The net profit attributable to shareholders for Q1 2024 was ¥118,693,454.55, down 9.41% year-on-year[14] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 9.11% to ¥112,881,250.41[14] - The company reported a basic earnings per share of ¥0.16 for Q1 2024, down from ¥0.17 in Q1 2023[34] - Net profit for the period was approximately 120.97 million, a decrease from 134.21 million in the previous period, representing a decline of about 9.3%[60] - Operating profit decreased to approximately 147.55 million from 169.61 million, reflecting a decline of about 13.0%[60] - Total profit for the period was approximately 147.79 million, down from 168.32 million, indicating a decrease of about 12.2%[60] Cash Flow and Assets - The net cash flow from operating activities was -¥101,987,265.98, reflecting an increase of 81.69% due to increased sales collections and reduced expenses[14] - Net cash inflow from operating activities in Q1 2024 was ¥1,556,812,682.63, compared to ¥1,453,896,838.72 in Q1 2023, indicating improved cash flow management[34] - The company's net cash flow from operating activities for Q1 2024 was -¥101,987,265.98, an improvement from -¥556,889,169.46 in Q1 2023[56] - The company reported a net cash outflow of -¥524,422,018.20 in Q1 2024, compared to -¥370,797,549.49 in Q1 2023, indicating a worsening cash position year-over-year[56] - As of March 31, 2024, the company's cash and cash equivalents decreased to ¥841,515,385.17 from ¥1,178,389,321.33 as of December 31, 2023, representing a decline of approximately 28.6%[56] - The total current assets increased to ¥7,313,843,040.11 as of March 31, 2024, compared to ¥7,031,044,519.89 as of December 31, 2023, reflecting a growth of about 4.0%[50] Assets and Liabilities - Total assets at the end of the reporting period reached ¥9,820,823,630.71, an increase of 2.67% from the end of the previous year[15] - Total assets increased to ¥9,820,823,630.71 in Q1 2024 from ¥9,565,383,273.17 in Q1 2023, showing growth in the company's asset base[30] - Total liabilities rose to ¥4,226,586,821.28 in Q1 2024, up from ¥4,088,813,874.21 in Q1 2023, indicating increased leverage[30] - The total liabilities decreased from ¥1,493,010,312.73 in December 2023 to ¥959,830,112.81 in March 2024, indicating a reduction of approximately 35.7%[50] - Shareholders' equity increased to ¥5,594,236,809.43 in Q1 2024 from ¥5,476,569,398.96 in Q1 2023, reflecting a stronger equity position[30] Product Development and Strategy - The company launched the new "777" brand focusing on health management and disease prevention, expanding its product line into various health sectors[21] - Key products such as "Kunchong Medicine Shenling Jianpi Granules" and "Shugan Granules" saw significant year-on-year growth of 48.42% and 81.72% respectively[21] - The company is actively enhancing its product pipeline in chronic disease management and elderly health, with several new drug applications under review by the National Medical Products Administration[22] - The company aims to become a leader in the silver-haired health industry, focusing on innovative product development and market expansion strategies[22] - The company aims to become a leader in the elderly health and chronic disease management sectors, focusing on the development of the "Sanqi" product line and the "Kunzhong Medicine 1381" series[41] Operational Efficiency and Management - The strategic development plan for 2024-2028 emphasizes resource integration and business expansion, with a commitment to enhancing internal talent development and management capabilities[41] - The company is undergoing a digital transformation in its production supply chain to achieve smart manufacturing and improve overall efficiency[41] - The company is focused on enhancing quality management and environmental health and safety (EHS) practices in collaboration with China Resources Sanjiu[41] - The company has established a motivational mechanism to support employee development and internal growth[41] - The strategic focus includes the integration of core business segments and the planning of production supply chain sub-strategies[41] - The company has completed the first year of integration with China Resources Sanjiu, laying a solid foundation for future collaboration[41] Shareholder Information - The top ten shareholders include China Industrial Bank and China Construction Bank, with the largest shareholder being China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holding 212,311,616 shares[45] Other Financial Metrics - Total operating costs for Q1 2024 were ¥1,681,940,225.73, down from ¥1,744,130,961.09 in Q1 2023, reflecting a cost reduction strategy[32] - Non-operating income for the period totaled RMB 5,812,204.14, with significant contributions from government subsidies amounting to RMB 5,480,417.70[40] - The company reported a non-operating loss from financial assets and liabilities amounting to RMB -321,823.57[40] - The company paid ¥201,779,948.98 in employee compensation during Q1 2024, an increase from ¥180,633,066.33 in the same period last year, reflecting a rise of approximately 11.4%[56] - The inventory increased to ¥1,786,507,593.86 as of March 31, 2024, from ¥1,688,247,280.29 as of December 31, 2023, marking an increase of about 5.8%[50] - Research and development expenses increased slightly to approximately 17.22 million from 16.51 million, an increase of about 4.3%[60] - Tax expenses decreased to approximately 26.82 million from 34.11 million, a reduction of about 21.3%[60] - Other comprehensive income after tax was negative 104,249.48, an improvement from negative 266,168.04 in the previous period[60] - The company reported a decrease in interest income to approximately 1.74 million from 2.67 million, a decline of about 34.9%[60] - The company experienced a foreign exchange loss of approximately 321,823.57, compared to a loss of 5,366,539.71 in the previous period[60] - The company’s financial expenses were approximately 6.34 million, slightly down from 6.48 million, a decrease of about 2.2%[60]

Financial Performance - The company reported a non-operating income of CNY 109,568,222.80 for 2023, a decrease from CNY 132,073,781.03 in 2022, reflecting a decline of approximately 17.0%[12]. - The company recorded a government subsidy of CNY 105,966,264.70 in 2023, down from CNY 128,687,005.17 in 2022, indicating a decrease of approximately 17.6%[12]. - The total non-current assets disposal income was CNY 11,158,867.07, a decrease from CNY 14,462,674.53 in 2022, reflecting a decline of about 22.9%[12]. - The company achieved a consolidated revenue of CNY 770,312.13 million, a year-on-year decrease of 6.99% due to optimization of the business structure and reduced external assistance[79]. - The total profit amounted to CNY 56,361.99 million, reflecting a year-on-year increase of 18.09%[79]. - The net profit attributable to shareholders reached CNY 44,468.00 million, up 16.05% compared to the previous year[79]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 33,511.17 million, showing a significant growth of 33.45%[79]. - The company's total operating revenue for the period was approximately ¥7.54 billion, a decrease of 2.33% compared to the previous year[92]. - The net cash flow from operating activities rose by 40.25% to ¥356,083,160.30 in 2023[134]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a 15% year-over-year growth[173]. Strategic Initiatives - The company completed the restructuring of its board and supervisory board on January 19, 2023, with the controlling shareholder changing to China Resources Sanjiu, marking a significant strategic shift[15]. - The company has outlined a three-year integration plan with China Resources Sanjiu, focusing on high-quality development during the 14th Five-Year Plan period[15]. - The company plans to deepen its engagement in chronic disease management and premium traditional Chinese medicine, aiming for market expansion and innovation[17]. - The company aims to become a leader in the aging health industry and has set strategic goals to enhance brand influence and competitive advantage in the market[65]. - The company is actively pursuing international cooperation and technology acquisition to support its strategic goals and enhance its global competitiveness[58]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for potential deals[173]. Research and Development - The company is committed to enhancing its research and development capabilities, focusing on innovative and differentiated generic drugs, particularly in the cardiovascular and chronic disease sectors[61]. - Total R&D investment for 2023 amounted to ¥125,173,560.88, representing 1.62% of operating revenue[113]. - R&D expenses increased due to higher capitalized research investments, reflecting a focus on innovation[90]. - R&D investment totaled 125.17 million yuan during the reporting period, focusing on innovative products for chronic disease management[160]. - The number of R&D personnel is 197, making up 3.90% of the total workforce[112]. Market Expansion - The company is focusing on the aging health sector, particularly in chronic disease management, and has established a comprehensive marketing model covering hospitals, grassroots medical institutions, and retail pharmacies[56]. - The OTC (over-the-counter) market for TCM is expected to grow significantly as public awareness of TCM's role in chronic disease prevention increases[54]. - The company is actively expanding its market presence in grassroots and clinic channels, enhancing its prescription drug penetration capabilities[143]. - Market expansion efforts include entering two new provinces, which are projected to increase market share by 5%[173]. Product Development - The company is focusing on the "Qunzhong Medicine 1381" platform to enhance its cultural brand and historical value[31]. - The establishment of the Yunnan Province Sanqi Research Institute aims to enhance innovation and research in the Sanqi industry[31]. - The company has over 600 approved product numbers and maintains a strong market position with core products like Xuesaitong and Artemisinin series, which have dominated the Chinese market for years[56]. - The injection of Xuesaitong (freeze-dried) saw a year-on-year growth of 22.65%, while the oral dosage form of Xuesaitong achieved a growth of 19.44%[143]. - The company’s product KPC1951 aims to establish leadership in the elderly health and chronic disease management sector[157]. Corporate Governance - The company is committed to enhancing corporate governance and integrating party leadership into its operations[156]. - The company has established a comprehensive internal control system and long-term supervision mechanism to enhance management effectiveness and risk prevention[199]. - A series of internal control management systems have been revised and improved, including investor relations and independent director work systems[199]. - The company has implemented a performance management system that aligns individual performance with organizational goals, enhancing overall efficiency[181]. Sustainability and Social Responsibility - The management team emphasized the importance of sustainability initiatives, committing to invest 30 million yuan in eco-friendly practices[173]. - The company has been recognized as a national technology innovation demonstration enterprise and has received multiple awards for its contributions to scientific and technological progress[61]. - The government has introduced policies to support the development of traditional Chinese medicine, indicating a long-term growth opportunity for the industry[37]. Financial Management - The company has a clear cash dividend policy that complies with its articles of association and shareholder resolutions[182]. - The company has not proposed a cash profit distribution plan despite having positive distributable profits for shareholders[197]. - The company has established a comprehensive evaluation and incentive mechanism for senior management to enhance performance accountability[187].

昆药集团股份有限公司（以下简称"公司"）已于2023年10月28日发布公司2023年第三季 度报告，为便于广大投资者更全面深入地了解公司2023年第三季度经营成果、财务状况，公 司计划于2023年11月23日下午14:00-15:00举行2023年第三季度网上业绩说明会，就投资者关 心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络互动方式召开，公司将针对2023年第三季度的经营成果及财务指 标等具体情况与投资者进行交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题 进行回答。 二、 说明会召开的时间、方式 证券代码：600422 证券简称：昆药集团 公告编号：2023-080 号 昆药集团股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）投资者可在2023年11月23日（星期四）下午14:00-15:00，通过互联网登陆上证路 演中心(http://roadshow.sseinfo.com/)，在线参与本次说明会，公司将及时回答投 ...

证券代码：600422 证券简称：昆药集团 公告编号：2023-079号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 担保情况概述 （1）担保事项履行的相关程序 为支持昆药集团股份有限公司（以下简称"公司"）旗下全资及控股子公司 2023 年 生产经营及业务发展需要，满足相关下属公司融资担保需求，经公司十届十四次董事 会及 2023 年第二次临时股东大会审议通过，2023 年度由公司及下属子公司为旗下公 司合计不超过人民币 9.52 亿元的银行融资授信业务提供连带责任担保，详见《昆药集 团股份有限公司关于 2023 年度担保计划的公告》（2023-027 号）和《昆药集团股份 有限公司 2023 年第二次临时股东大会决议公告》（2023-030 号）。 （2）担保概况 为支持旗下全资及控股子公司生产经营及业务发展，2023 年 11 月 8 日，在上述 批准范围内公司发生如下担保（单位：万元）： 1 被担保人：保山市民心药业有限责任公司（以下简称"保山民心" ...

证券代码：600422 证券简称：昆药集团 公告编号：2023-078号 一、 2015年非公开发行募集资金基本情况 经中国证券监督管理委员会《关于核准昆药集团股份有限公司非公开发行股票的 批复》（证监许可[2015]2088 号）文核准，并经上海证券交易所同意，公司采用非公 开发行新增股份 53,214,133 股，面值 1 元/股，发行价格 23.49 元/股，共募集资金总额 为人民币 1,250,000,000.00 元，扣除承销费、保荐费、律师费及其他相关发行费用后 募集资金净额为 1,238,694,785.87 元。上述募集资金已于 2015 年 10 月 26 日存入公司 在中国银行股份有限公司昆明市高新支行开立的人民币募集资金专户(账号： 134042351630，账户名称：昆药集团股份有限公司)，并经中审亚太会计师事务所（特 殊普通合伙）验证，出具中审亚太验[2015]020021 号《验资报告》。 二、 2015 年非公开发行募集资金存放和管理情况 1、为规范募集资金的存放、使用与管理，提高募集资金使用效益，保护投资者 的合法权益，2013年起公司根据《中华人民共和国公司法》《中华人民共和 ...

Financial Performance - Total revenue for Q3 2023 was approximately ¥1.84 billion, a decrease of 6.36% compared to the same period last year[9] - Net profit attributable to shareholders was approximately ¥162.64 million, an increase of 4.20% year-on-year[9] - Net profit excluding non-recurring gains and losses was approximately ¥133.21 million, up 15.61% from the previous year[9] - Total operating revenue for the first three quarters of 2023 was CNY 5,610,863,771.76, a decrease of 9.35% compared to CNY 6,192,724,407.85 in the same period of 2022[44] - Operating revenue for the third quarter was approximately CNY 5.61 billion, a decrease of 9.4% compared to CNY 6.19 billion in the same period last year[46] - Total operating costs decreased to approximately CNY 5.17 billion, down 10.7% from CNY 5.79 billion year-over-year[46] - Net profit for the third quarter was approximately CNY 396.23 million, an increase of 4.2% from CNY 380.26 million in the previous year[49] - Basic earnings per share for the third quarter increased to CNY 0.51, compared to CNY 0.49 in the same quarter last year[51] - The company reported a total profit of approximately CNY 476.78 million, an increase of 2.3% from CNY 466.70 million year-over-year[49] - Other comprehensive income after tax was negative CNY 1.09 million, compared to a positive CNY 12.07 million in the same quarter last year[50] Cash Flow and Assets - Cash flow from operating activities showed a net outflow of approximately ¥36.37 million, a decrease of 68.44% year-to-date[11] - Cash inflow from operating activities totaled approximately CNY 5.64 billion, down 10% from CNY 6.27 billion year-over-year[51] - The net cash flow from operating activities was -$36.37 million, an improvement from -$115.25 million in the previous period[54] - Cash outflow from operating activities totaled $5.67 billion, down from $6.38 billion year-over-year[54] - The ending balance of cash and cash equivalents was $1.06 billion, a decrease from $1.18 billion in the previous year[56] - The company experienced a net decrease in cash and cash equivalents of $493.08 million, compared to a decrease of $271.52 million in the previous year[56] - Total assets at the end of the reporting period were approximately ¥9.29 billion, a decrease of 1.50% from the end of the previous year[11] - Total assets decreased to CNY 9,290,529,604.89 from CNY 9,431,958,219.84, reflecting a decline of approximately 1.5%[36] - The company's total liabilities decreased to CNY 3,881,262,061.63 from CNY 4,289,436,247.47, a reduction of about 9.5%[36] - Current liabilities decreased to CNY 3,451,363,584.62 from CNY 3,888,865,825.80, a reduction of about 11.3%[36] - Cash and cash equivalents decreased to CNY 1,125,189,467.52 from CNY 1,658,391,640.50, representing a decline of approximately 32.1%[40] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,819[19] - The largest shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holds 28.01% of the shares[21] - Shareholders' equity attributable to the parent company was approximately ¥5.25 billion, an increase of 5.29% year-on-year[11] - The company's equity attributable to shareholders increased to CNY 5,246,812,921.76 from CNY 4,983,023,495.62, an increase of approximately 5.3%[36] Strategic Initiatives - The company is progressing with the integration with China Resources Sanjiu, focusing on strategic, organizational, and cultural alignment[14] - The company launched the "Lecheng" cultural system to enhance internal corporate culture and operational guidelines[14] - The marketing organization transformation project was initiated to improve efficiency and clarify marketing strategies[14] - The company completed a mid-term review of its "14th Five-Year" strategic plan, further clarifying strategic goals[14] - The company aims to enhance its market penetration and share in the "silver economy" health sector through strategic initiatives and partnerships[17] - The company is focused on building a robust value chain system based on the Sanjiu business model to support its growth strategy[17] Product Development and Research - The CHC segment achieved over 30% growth in key products during Q3, including major varieties like Shenling Baizhu Granules and Shugan Granules[17] - The company’s core product, Xuesaitong oral solution, saw a year-on-year growth of over 10%, while Xuesaitong soft capsules grew by over 20%[17] - The company completed the integration of primary channel distributors across 20 provinces, significantly enhancing average sales per customer[17] - The company’s self-developed anti-malarial drug, Dihydroartemisinin Piperaquine Tablets, received WHO-PQ certification, facilitating international market expansion[18] - Clinical trials for the ischemic stroke drug KYAZ01-2011-020 have commenced at over 20 research centers, progressing smoothly[18] - The company is actively pursuing multiple generic drug projects, with the first domestic consistency evaluation submission for a psychiatric injectable already completed[18] Legal and Compliance - The company has successfully concluded all administrative confirmation, review, and litigation procedures regarding the land use rights dispute, confirming the ownership of the land without any disputes[30] - The company faced a lawsuit regarding land use rights, with a claim for compensation of 80 million RMB, which was ultimately dismissed by the court[30] - The company has maintained transparency regarding its stock repurchase activities and the outcomes of legal disputes, ensuring stakeholders are informed[30] - The company continues to navigate legal challenges while focusing on maintaining clear ownership of its assets[30] Stock and Incentive Plans - The company completed the repurchase and cancellation of 128,000 restricted stocks from a former executive due to their departure, reducing the total number of shares from 758,127,769 to 757,986,969[27] - The company repurchased and canceled 14,080 restricted stocks from another former executive, further reducing the number of incentive plan participants from 8 to 7[27] - The company repurchased and canceled a total of 657,927 restricted stocks from a former executive, which included stocks that had not yet been released from restrictions[27] - The company’s total number of shares has been adjusted multiple times due to the repurchase of restricted stocks, reflecting changes in the incentive plan participants[27] - The company’s stock incentive plan has seen a reduction in eligible participants due to multiple executive departures, impacting the total number of restricted stocks[27] Research and Development Expenses - Research and development expenses decreased significantly to CNY 43.33 million, down 41.3% from CNY 73.79 million in the previous year[46] - Financial expenses decreased significantly to CNY 9.46 million, down 71% from CNY 32.79 million in the previous year[46]

根据《上市公司独立董事管理办法》《上市公司治理准则》《上海证券交易所股票 上市规则》和《公司章程》的有关规定，我们作为昆药集团股份有限公司(以下简称"公 司")的独立董事，已于会前获得并审阅了相关议案及材料。本着实事求是的态度，在 认真审查相关资料后，现对公司十届十九次董事会相关事项发表事前认可意见如下： 1、 关于公司参与投资新设公司暨关联交易事项的议案 本次关联交易的定价依据公允合理，交易行为公平、公正、合理。本次参与投资 新设云南省三七研究院有限公司，符合公司战略方向及长远发展需求，不存在损害公 司及其股东特别是中小股东利益的情形。本次交易事项符合《公司法》《证券法》等 有关法律法规和《公司章程》的规定。我们同意将该项关联交易事项提交公司董事会 审议。 独立董事：刘珂 辛金国 杨智 关于公司十届十九次董事会相关事项的事前认可意见 昆药集团股份有限公司独立董事 本次参与投资新设云南省三七研究院有限公司，符合公司长远发展需求。本次关 联交易的定价依据公允、合理，不存在损害公司及其股东特别是中小股东利益的情形。 在审议上述议案时，公司关联董事已按规定回避表决，董事会表决程序合法。因此， 我们同意公司关于参与投 ...